

Charity Registration No. 20077945

Company Registration No. 496464 (Republic of Ireland)

BREAKTHROUGH CANCER RESEARCH
ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

BREAKTHROUGH CANCER RESEARCH

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Breda O'Sullivan Doreen O'Mahony Enda Lynch Michael McMahon Jeffery Long Angela Gillina Kasia Whysall	(Appointed 1 January 2022) (Appointed 28 March 2022) (Appointed 2 March 2023) (Appointed 2 March 2023)
Secretary	L&P Trustee Services Limited	
Charity number	20077945	
Company number	496464	
Principal address	Glenlee, Western Road, Cork.	
Registered office	Glenlee, Western Road, Cork.	
Auditor	Moore Chartered Accountants & Statutory Audit Firm, 83 South Mall, Cork.	
Bankers	Allied Irish Bank, College Branch, Cork.	
Solicitors	Ronan Daly Jermyn, 2 Park Place, City Gate Park, Mahon Point, Co. Cork.	

BREAKTHROUGH CANCER RESEARCH

CONTENTS

	Page
Trustees' report	1 - 6
Statement of trustees' responsibilities	7
Independent auditor's report	8 - 10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 24

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Companies Act 2014 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

The main object of Breakthrough Cancer Research (Breakthrough), a not-for-profit company, which has charitable status (Registered Charity Number: 20077945, Revenue Number: CHY19801), is the raising and application of money and other resources for the purpose of education and research and development in the field of cancer prevention, diagnosis and treatment.

The activities are funded by receipt of monies from philanthropic supporters, corporate supporters and through individual giving, community fundraising and events.

Breakthrough Cancer Research focuses on:

- funding world-class cancer research into poor prognosis cancer, which are poorly served by current treatment options;
- facilitating collaboration between scientists and clinicians across Ireland and Internationally; and
- translating lab discoveries into new effective treatments for cancer patients.

The company / charity supports research at a number of Irish Host Institutions (e.g. Universities) but also has a historic but arm's length relationship with the translational research centre formerly known as Cork Cancer Research Centre in UCC and significantly funds their relevant programmes.

Breakthrough Cancer Research funds research directly, investing fundraised money in line with our research strategy, objectives and priorities. We also leverage additional research investment for our research strategy and priorities through competitive grant programmes.

Achievements and performance

In 2022 fundraising and research made huge strides to achieve our research goals and priorities to invest in research which will positively impact patient treatment and care. Income exceeded €2 million for the second year ever since our inception and we invested €1,530,097 directly into research while leveraging an additional €859,802 for projects which aligned with our research strategy and priorities. Breakthrough also provided support to the research community, new treatments for patients and evidence-based information and tools to the public and cancer patients. We continue to strengthen existing relationships while expanding our reach and impact both nationally and internationally. In 2022 significant investment was also made in building greater brand awareness, building on the success of recent award-winning campaigns, to find novel and effective ways to inspire support through greater understanding of the power of research to make more survivors of cancer. A series of very successful campaigns were executed including a new brand campaign called Every Breakthrough Brings Us Closer and a new National Flag Day coinciding with World Cancer Research Day (September 24th).

Some highlights of our activities in 2022 include:

Cancer research: In 2022 funding was provided to fund staff / researchers, consumables, infrastructure and equipment for cancer research to improve cancer care and outcomes with patient benefit at the core. As part of our new 5-year Research Strategy 2022 - 2027 (Making More Survivors) we revised our research priorities. Nineteen project grants were awarded during the year, which aligned with Breakthrough's updated research priorities to:

- Increase our research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- Improve integration of cancer research into cancer care in Ireland and increase clinical capacity by prioritising funding for projects and programmes with significant clinical engagement.
- Fund the discovery and development of new therapies, surgical approaches and technologies, including biological and immune approaches, to improve cancer treatments.
- Fund research, which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.
- Invest in research harnessing the potential of big data to improve cancer detection, personalised treatment and patient outcomes.
- Invest in research-led innovation at every stage of the cancer patient journey from first diagnosis through to treatment, clinical trials and palliative care to improve survival and quality of life.

In 2022 we launched the inaugural All-Ireland Cancer Network (AllCaN) grant programme. The AllCaN Grant Programme was created as part of Breakthrough's new 5-year research strategy (Making More Survivors), to support and facilitate knowledge sharing between exemplary teams in institutions across the island of Ireland, who are taking on less survivable cancers. This €1million investment was awarded to an all-Ireland network led by Prof. Jacintha O'Sullivan (Trinity St. James's Cancer Institute, (TSJCI)), and co-led by Prof. Helen Coleman (Queen's University Belfast (QUB)) and Prof. Juliette Hussey (TSJCI). The collaboration links six major academic institutions across the island of Ireland - Trinity College Dublin (TCD), QUB, UCC, Royal College of Surgeons of Ireland (RCSI), UCD and University of Galway - along with their associated hospitals, the National Cancer Control Programme and the Belfast Health and Social Care Trust. The inaugural AllCaN programme is focused on improving outcomes of patients with Barrett's oesophagus and oesophageal cancer and will commence in early 2023.

In 2022, Breakthrough Cancer Clinical Research Fellowship was launched for medical graduates dedicated to a career in the field of oncology, haematology or a related discipline. This 5-year programme will facilitate patient focused research in UCC and its affiliated hospitals to help develop and improve cancer treatments for Irish patients. Dr Maeve Hennessy was awarded the first Breakthrough Cancer Clinical Research Fellowship. Over two years Dr Hennessy will investigate methods to predict women's response to breast cancer chemotherapy.

In 2022, the second Cancer Immunology Research Fellowship (CIRF), a partnership between Breakthrough and 5 for Fight was awarded to a researcher in the Trinity St. James Institute. Breakthrough also awarded the two PhD scholarships, one Musgrave Cancer Research PhD Scholar (Pancreatic cancer) and one Breakthrough PhD Scholar (Lung cancer) and ran the Summer Scholarship Programme for the second year. Through this programme five young researchers were funded. One Breakthrough project grant was also awarded to fund research into oncology nutrition in the LYSA Clinical Trial in CUH.

All supported researchers and institutions are encouraged to work with Breakthrough to leverage our support to secure additional funding from other National and International funders. One mechanism Breakthrough leverages our research funding is a member of the Health Research Charities Ireland (HRCI) and our participation in bi-annual HRCI-HRB Joint Funding Scheme. This innovative scheme allows us to nominate peer reviewed projects, which fulfil our research priorities and if selected, leverage 50% funding from the Health Research Board (HRB), while providing the additional 50% from the charity. In 2021 we opened a new round of this scheme and 19 expressions of interest were received, with 9 projects invited to submit full applications. Four projects, the maximum allowed, were put forward to the final review panel following an extensive peer and Public Patient Involvement (PPI) review process. Two new projects were supported through this programme both in the RCSI. One explores the rehabilitation needs of people with brain tumours in Ireland, the other investigates a new multiple myeloma model for treatment discovery.

Breakthrough also participates in the Irish Research Council's (IRC) Enterprise Scheme, another partnership programme where the leveraged funding is approximately €4 for every €1 invested by Breakthrough. In 2022, five of the seven applications in which we partnered were successful through this programme. These postgraduate level grants are in UCC, UCD and Dublin City University (DCU). These projects focused on uveal melanoma, childhood leukaemia, oesophageal cancer, pancreatic and prostate cancers. We were also successful in partnering on one New Foundation Grant on using a proteomic strategy to identify novel targets in ovarian cancer in Maynooth University (MU).

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Breakthrough successfully funded a 3-year oesophageal cancer project in UCC through a new 50:50 co-funding scheme - DevelopMed, a Marie Skłodowska-Curie COFUND Action, which is an International Training and Career Development Fellowship Programme coordinated by Systems Biology Ireland in UCD.

2022 also saw progression of the strategic partnership called Precision Oncology Ireland. The consortium, supported by Science Foundation Ireland, brings together 5 Universities, 6 Cancer Research Charities and 7 International Companies. Breakthrough is part of this consortium which aims to develop new diagnostics and therapeutics for personalised cancer treatments. In addition, Breakthrough Cancer Research provided the fourth year of five years funding for The Professor Gerald O'Sullivan Chair in Cancer Research, a joint appointment between UCC and the South-South West Hospital Group and which is funded by Breakthrough and the HSE.

Thus, at the end of 2022 Breakthrough is funding research at ten Irish Host Institutions as well as at Queen's University Belfast in Northern Ireland. More details on these and other projects, the specific cancer types we targeted and other Breakthrough outputs can be found in our annual report and website.

Cancer treatment and support: The charity also continues to fund the treatment of patients as needed with Electro-Chemotherapy, a non-surgical technique for the treatment of skin based cancers offered upon referral at Cork University Hospital.

Commencing in 2016 funds have been provided by Breakthrough to support the development and dissemination of four books providing advice and recipes for patients experiencing cancer induced weight loss. All of these books are provided to the public for free. In 2022 an additional publication called "The Truth Behind Food & Cancer" was launched and disseminated and funds were provided to update and expand the award winning "Good Nutrition for Cancer Recovery" cookbook and redevelop resources for patients experiencing Dysphagia to respond to the new International Dysphagia Diet Standardisation Initiative (IDDSI).

Cancer prevention: In 2022 we proceeded with the second year of two year UV (Skin Cancer) Awareness programme, targeting men with outdoor hobbies and jobs. Additional awareness campaigns were undertaken in conjunction with the Irish Cancer Prevention Network and with consortia on Gynaecological cancers. Breakthrough worked with a national consortium in the "This is Go" Campaign to raise awareness of ovarian cancer symptoms.

Public-Patient involvement: In 2022 members of the Breakthrough PPI panel participated in a number of grant reviews and also interviews with researchers to allow for the presentation of research concepts in an acceptable way. They also participated in a 2-day Research Communication Workshop which Breakthrough developed and facilitated, and which included 17 Breakthrough-funded early career researchers. PPI panellists also judged the best lay presentation of our Summer Scholars.

PPI panellists also participated in and attended the 58th Irish Association of Cancer Research Conference, for which Breakthrough is a sponsor and public events including the Cancer Research showcase in UCC. Trained PPI representatives are also active members of grant management committees for strategic projects and initiatives e.g. Women's Survivorship Clinic.

Operations: The research department grew in 2022 at research officer level and the expansion of the team and implementation of a new Grant Management System were targeted to keep pace with the management of the expanding research portfolio. Additional headcount was also added to support community and event fundraising which helped to drive greater success in these income streams.

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Future Plans

In 2023 a new Strategic Plan will commence, developed through a planning process undertaken in 2022. The strategy builds on immense success to date and sets out an ambitious goal to greatly expand our impact for people with cancer and builds on our recently launched research strategy – 'Making More Survivors'.

Multiple stakeholders were consulted, to inform the direction and priorities for the next four years. The consultation included facilitated sessions with the Board, Patient and Public Involvement representatives (PPI) and research leaders; surveys of staff and supporters; and 1-1 interviews with key external stakeholders. After review of stakeholder consultation outputs, including challenges to be addressed and opportunities to be pursued, as well as analysing the context within which Breakthrough Cancer Research operates and the organisation itself, the Steering Team agreed on six key areas of focus for the period of the strategy setting our direction for the next four years. A strategic objective was agreed for each of these areas. Metrics and actions to demonstrate how these strategic objectives will be measured and delivered were agreed.

Broadly, significant growth is planned to increase fundraised income for the charity and support greater investment in impactful research. Further detail is available in the Strategic Plan published on our website.

Financial review

The results for the year are set out on page 11.

In terms of financial performance for 2022, Breakthrough reports a deficit of €151,604. Income and expenditure were monitored against our annual budget and financial progress was reported in detail to our Board at regular intervals throughout the year.

It is the policy of the company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six months' expenditure and with consideration of research funding commitments in the year. It is the policy of the company to take on multi-year research commitments which will be met by cash reserves and anticipated future income which are based on conservative projections derived from prior history. The company considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Principal risk and uncertainty

The main risk facing the company is the financial risk associated with the nature of its revenue source being donations which are dependent on the prevailing economic climate which is currently quite challenging due to inflation and the consequent high cost of living and significant global events such as the conflict in Ukraine.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. The company has assessed the major risks to which the company is exposed and are satisfied that systems are in place to mitigate exposure to major risks.

Post reporting date events

The trustees are of the view that the fundraising climate for 2023 could remain challenging as a result of the conflict in Ukraine, other external events like the earthquake in Syria/Turkey and the impact of inflation on supporters. This could have some impact on the income of the company for 2023. Nonetheless the trustees are of the view that this will not impact on the ability of the company to operate as a going concern due to significant levels of reserves the company has at the end of 2022 and the ability of the company to manage its expenditure on research and other activities. A new four year strategy, commencing in 2023 is targeting investment to grow the income of the company enable increasing our research investment.

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management

The organisation is a charitable company limited by guarantee. The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required, not exceeding €1.

The charity was established under a Memorandum of Association which established the objects and powers of the charitable company is governed under its Constitution and managed by a board who meet several times a year. A Scientific Advisory Committee and Patient Panel provide objective options and insight into the charities research priorities and direction.

Breakthrough Cancer Research demonstrates openness, transparency and integrity to our donors, supporters, volunteers and funding partners by operating rigorously to the triple lock standards set out by the Charity Institute of Ireland - ethical fundraising, transparent annual financial reporting and governance.

Breakthrough has formally adopted, is signed up to and is fully committed to achieving the guidelines for charitable organisation fundraising from the public. Breakthrough Cancer Research's annual accounts are independently audited every year and we prepare our accounts in accordance with Irish accounting standards and with reference to the Statement of Recommended Practice (SORP) for charities. The board of Breakthrough is fully compliant with the Governance Code for the Community and Voluntary Sector and the Charities Governance Code set out by the regulator in 2018. Breakthrough Cancer Research maintained the Charities Institute Ireland Triple Lock Standard for 2022 and is currently one of 60 charities in Ireland to have achieved this standard of best practice.

The trustees' who served during the year and post year end to date were:

Breda O'Sullivan	
Brendan Buckley	(Resigned 12 December 2022)
Derek Power	(Resigned 24 January 2022)
Sean Ryan	(Resigned 24 January 2022)
Doreen O'Mahony	
Enda Lynch	
Michael McMahon	(Appointed 1 January 2022)
Jeffery Long	(Appointed 28 March 2022)
Angela Gillina	(Appointed 2 March 2023)
Kasia Whysall	(Appointed 2 March 2023)

If the Board identifies a need for new members, it commences a process to recruit. New members of the Board are identified through Board Match or through the Trustees own networks. New members are appointed by unanimous agreement of the existing members and can serve two terms in line with the Scheme of Incorporation. All new Trustees take part in an induction to ensure full understanding of their role and the responsibilities and are offered training in Board Membership and Leadership. Three Trustees left in 2022, two in Q1 and one in late Q4 and two Trustees was added in Q1 2022, with two further trustees appointed in Q1 2023. Extensive training and review was undertaken by all trustees in 2022 on the Charities Governance Code.

Volunteers make a substantial contribution to the mission, strategy and activities of the organisation in a multitude of ways. The volunteer Trustees ensure that the mission and values of Breakthrough Cancer Research are safeguarded and that the Scheme of Incorporation is kept under review to reflect Breakthrough's circumstances and aspirations. The Board ensures that Breakthrough has clear plans with strategic and long-term goals that Breakthrough's activities are monitored and its risks are managed. Volunteers on our Scientific Advisory Committee provide expertise specific and essential to the research strategy and activities and volunteers on the Public Patient Involvement Panel ensure that the lived experience of people with cancer is incorporated into our research strategy and activities. Volunteers also contribute significantly to fundraising.

BREAKTHROUGH CANCER RESEARCH

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Auditor

In accordance with the Companies Act 2014, section 383(2), Moore continue in office as auditors of the company.

Disclosure of information to auditor

Each of the trustees' in office at the date of approval of this annual report confirms that:

- so far as the trustee is aware, there is no relevant audit information of which the company's auditors are unaware, and
- the trustee has taken all the steps that they ought to have taken as a trustee in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

The trustees' report was approved by the Board of Trustees.



Michael McMahon
Trustee



Jeffery Long
Trustee

Dated: 11/09/23

BREAKTHROUGH CANCER RESEARCH

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2022


The trustees, who are also the directors of Breakthrough Cancer Research for the purpose of company law, are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and Accounting Standards (Ireland Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the incoming resources and application of resources, including the income and expenditure, of the company for that year.


In preparing these financial statements, the company:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The trustees' are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



Michael McMahon
Trustee



Jeffery Long
Trustee

Dated: 11/01/23

BREAKTHROUGH CANCER RESEARCH

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF BREAKTHROUGH CANCER RESEARCH

Opinion

We have audited the financial statements of Breakthrough Cancer Research (the 'company') for the year ended 31 December 2022 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies as set out in note 1. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*. In applying that framework, the Trustees' have elected to have regard to the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with FRS 102 (revised 1 January 2019) ("the Charities SORP").

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2022 and of its deficit for the year then ended;
- have been properly prepared in accordance with FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* as applied in accordance with provisions of the Companies Act 2014 and having regard to the Charities SORP; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

BREAKTHROUGH CANCER RESEARCH

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BREAKTHROUGH CANCER RESEARCH

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report this fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of the audit.

In our opinion the accounting records of the company are sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge we and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the trustees' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of trustees' remuneration and transactions are not complied with by the company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of trustees for the financial statements

As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the company's ability to continue as a going concern, disclosing if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

BREAKTHROUGH CANCER RESEARCH

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BREAKTHROUGH CANCER RESEARCH

A further description of our responsibilities for the audit of the financial statements is located on the Irish Auditing and Accounting Supervisory Authority's website at: https://www.iaasa.ie/getmedia/b2389013-1cf6-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf. This description forms part of our auditor's report.

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



John Callaghan
for and on behalf of Moore
Chartered Accountants &
Statutory Audit Firm,
83 South Mall,
Cork.

Date signed:

22/9/22.

BREAKTHROUGH CANCER RESEARCH

STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds €	Restricted funds €	Total 2022 €	Total 2021 €
<u>Income and endowments from:</u>					
Legacies	3	122,976	-	122,976	234,513
Charitable activities	4	1,635,976	628,438	2,264,414	2,072,264
Other income	5	(41,704)	-	(41,704)	140,549
Total income		1,717,248	628,438	2,345,686	2,447,326
<u>Expenditure on:</u>					
Raising funds	6	441,089	-	441,089	297,753
Charitable activities	7	526,104	-	526,104	523,995
Research costs	9	1,177,996	352,101	1,530,097	1,308,124
Total resources expended		2,145,189	352,101	2,497,290	2,129,872
Net (outgoing)/incoming resources before transfers		(427,941)	276,337	(151,604)	317,454
Gross transfers between funds	12	583,511	(583,511)	-	-
Net income/(expenditure) for the year/ Net movement in funds		155,570	(307,174)	(151,604)	317,454
Fund balances at 1 January		257,558	497,260	754,818	437,364
Fund balances at 31 December		413,128	190,086	603,214	754,818

BREAKTHROUGH CANCER RESEARCH

BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022 €	€	2021 €	€
Fixed assets					
Tangible assets	13		28,922		7,266
Current assets					
Debtors	15	68,008		20,505	
Cash at bank and in hand		1,106,378		1,243,375	
		<u>1,174,386</u>		<u>1,263,880</u>	
Creditors: amounts falling due within one year	16	<u>(600,094)</u>		<u>(516,328)</u>	
Net current assets			574,292		747,552
Total assets less current liabilities			<u>603,214</u>		<u>754,818</u>
Income funds					
Restricted funds	17	190,086		497,260	
Unrestricted funds		413,128		257,558	
		<u>603,214</u>		<u>754,818</u>	

The financial statements were approved by the board of trustees on 11/01/2023 and signed on its behalf by:



Michael McMahon
Trustee



Jeffery Long
Trustee

BREAKTHROUGH CANCER RESEARCH

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2022 €	€	2021 €	€
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	21		(113,625)		433,038
Investing activities					
Purchase of tangible fixed assets		(27,177)		(7,461)	
Net cash used in investing activities			(27,177)		(7,461)
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(140,802)		425,577
Cash and cash equivalents at beginning of year			1,243,375		817,798
Cash and cash equivalents at end of year			1,102,573		1,243,375
Relating to:					
Cash at bank and in hand			1,106,378		1,243,375
Company visa card included in creditors payable within one year			(3,805)		-

BREAKTHROUGH CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

Breakthrough Cancer Research is a company limited by guarantee and has no share capital. In the event of the company being wound up, the liability in respect of the guarantee is limited to €1 per member of the charity. The registered office of the charity is Glenlee, Western Road, Cork which is also the address where the charity conducts its business.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), "Accounting and Reporting by Charities" the Statement of Recommended Practice for charities applying FRS102 and the requirements of the Companies Act 2014. The company is a Public Benefit Entity as defined by FRS102.

Breakthrough Cancer Research has applied the recommendations contained in the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) which is effective from 1 January 2019 in preparing the financial statements.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacies are recognised on receipt or otherwise if the company has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

BREAKTHROUGH CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies **(Continued)**

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the company's work or for specific artistic projects being undertaken by the company.

1.5 Expenditure

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the company's activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities. The bases on which support costs have been allocated are set out in note 8.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% S.L
Computers	33.33% S.L

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Impairment of fixed assets

At each reporting end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

BREAKTHROUGH CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

1.10 Taxation

No charge to taxation arises due to the tax exempt status of Breakthrough Cancer Research. This is in accordance with the provisions of Section 207 (as applicable to companies by Section 76), Section 609 (Capital Gains Tax) and Section 266 (Deposit Interest Retention Tax) of the Taxes Consolidation Act, 1997 under charity number CHY19801.

The company is eligible for the scheme of tax relief for donations to eligible charities and approved bodies in relation to Income tax refunds on donations in excess of €250 (Section 848A Taxes Consolidation Act, 1997).

As a charity, the company cannot recover VAT paid. As such, all VAT is expensed in the statement of financial activities. The company can however recover some VAT incurred through the VAT compensation scheme for charities and any monies recouped through this scheme are shown as part of 'Other income' in the financial statements.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

2 Critical accounting estimates and judgements

In the application of the company's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The directors are of the view that there are no judgements (apart from those involving estimates) in applying their accounting policies that have had a significant effect on amounts recognised in the financial statements.

Key sources of estimation uncertainty

The directors are of the view that there are no estimates or assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities.

3 Legacies

	2022 €	2021 €
Legacies receivable	122,976	234,513

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

4 Charitable activities

	Corporate Funds €	Challenges & Events €	Community €	Individual Giving €	Campaigns €	Major Gifts €	Total 2022 €	Total 2021 €
Income from charitable activities	471,636	518,071	528,808	333,070	176,263	236,566	2,264,414	2,072,264
Analysis by fund for the year ended 31 December 2022								
Unrestricted funds	439,106	282,437	379,210	268,997	176,226	90,000	1,635,976	1,219,307
Restricted funds	32,530	235,634	149,598	64,073	37	146,566	628,438	852,957
	471,636	518,071	528,808	333,070	176,263	236,566	2,264,414	2,072,264
Analysis by fund for the year ended 31 December 2021								
Unrestricted funds	369,667	19,361	275,172	230,972	204,135	120,000	1,219,307	1,219,307
Restricted funds	196,862	102,021	40,968	154,429	12	358,665	852,957	852,957
	566,529	121,382	316,140	385,401	204,147	478,665	2,072,264	2,072,264

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

5 Other income

	2022 €	2021 €
Other income	7,845	-
Grant income	(49,549)	140,549
	<u>(41,704)</u>	<u>140,549</u>

Included in grant income in 2021 is an amount of €90,500 received from An Pobal in relation to a COVID-19 Stability Scheme grant, which was a restricted grant only to be used for eligible expenditure as set out in the grant letter of offer. The grant was fully spent in 2021 and used for eligible expenditure in areas of advertising, event costs and support / governance costs.

In addition, included in grant income in 2021 are amounts received from Revenue totalling €50,049 in relation to the EWSS scheme. This amount was subsequently repaid to Revenue in 2022 as it transpired that not all of the eligibility criteria had been met. This repayment of EWSS monies was offset by the receipt of a separate grant of €500 during 2022, which resulted in the negative grant income of €49,549 being reflected in the financial statements for the current financial year.

6 Raising funds

	2022 €	2021 €
<u>Fundraising and publicity</u>		
Challenges and event costs	40,047	18,475
Campaign costs	78,263	92,039
Corporate costs	11,615	4,707
Major gift costs	24	1,062
Advertising	67,016	39,802
Other fundraising costs	7,200	2,092
Staff costs	236,924	139,576
	<u>441,089</u>	<u>297,753</u>

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

7 Charitable activities

	Total 2022 €	Total 2021 €
Depreciation and impairment	5,521	4,055
Printing, postage and stationery	6,850	6,903
Advertising	329,169	306,038
Sundry Expenses	6,175	4,653
Refund of donations	-	40,160
	<u>347,715</u>	<u>361,809</u>
Share of support costs (see note 8)	124,086	116,592
Share of governance costs (see note 8)	54,303	45,594
	<u>526,104</u>	<u>523,995</u>

8 Support costs

	Support costs €	Governance costs €	2022 €	2021 €	Basis of allocation
Staff costs	49,022	17,583	66,605	58,151	Time incurred
Rent	25,000	-	25,000	25,000	Actual invoices
Power, Light and Heat	11,089	-	11,089	6,297	Actual invoices
Insurance	4,643	-	4,643	5,439	Actual invoices
Computer Costs	13,379	-	13,379	8,660	Actual invoices
Motor & Travel Costs	69	-	69	3,509	Actual invoices
Subscriptions	3,713	-	3,713	4,223	Actual invoices
Bank Charges	5,985	-	5,985	5,641	Actual invoices
Office costs	7,470	-	7,470	8,696	Actual invoices
Telephone Costs	3,716	-	3,716	4,780	Actual invoices
Audit fees	-	7,360	7,360	7,194	Actual invoices
Legal and professional	-	29,360	29,360	24,596	Actual invoices
	<u>124,086</u>	<u>54,303</u>	<u>178,389</u>	<u>162,186</u>	
Analysed between Charitable activities	<u>124,086</u>	<u>54,303</u>	<u>178,389</u>	<u>162,186</u>	

The only fees paid to auditor's in the current and previous periods were in respect of the statutory audit.

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

9 Research costs

	Unrestricted funds	Restricted funds	Total 2022 €	Total 2021 €
General research	839,524	352,101	1,191,625	1,063,901
Education and information	197,698	-	197,698	149,408
Research wages and salaries	140,774	-	140,774	94,815
	<u>1,177,996</u>	<u>352,101</u>	<u>1,530,097</u>	<u>1,308,124</u>
For the year ended 31 December 2021	<u>823,499</u>	<u>484,625</u>		<u>1,308,124</u>

10 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the company during the year.

11 Employees

The average monthly number of employees during the year was:

	2022 Number	2021 Number
Employees	<u>9</u>	<u>6</u>
Employment costs	2022 €	2021 €
Wages and salaries	388,701	273,676
Social security costs	41,455	12,405
Other pension costs	12,676	5,715
	<u>442,832</u>	<u>291,796</u>

There were no employees whose annual gross salary was €70,000 or more.

12 Transfers

During the financial year, €583,511 of restricted funds were transferred to unrestricted funds on agreement with the donor of the funds in question.

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

13 Tangible fixed assets			
<i>Current financial year</i>	Fixtures and fittings	Computers	Total
	€	€	€
Cost			
At 1 January 2022	8,684	14,194	22,878
Additions	18,150	9,027	27,177
At 31 December 2022	26,834	23,221	50,055
Depreciation and impairment			
At 1 January 2022	8,683	6,929	15,612
Depreciation charged in the year	618	4,903	5,521
At 31 December 2022	9,301	11,832	21,133
Carrying amount			
At 31 December 2022	17,533	11,389	28,922
At 31 December 2021	-	7,266	7,266
14 Financial instruments	2022	2021	
	€	€	
Carrying amount of financial assets			
Debt instruments measured at amortised cost	54,097	12,200	
Carrying amount of financial liabilities			
Measured at amortised cost	557,419	507,762	
15 Debtors	2022	2021	
Amounts falling due within one year:	€	€	
Trade debtors	54,097	12,200	
Prepayments and accrued income	13,911	8,305	
	68,008	20,505	

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

16 Creditors: amounts falling due within one year

	2022 €	2021 €
Company visa card	3,805	-
Other taxation and social security	42,675	8,566
Trade creditors	21,389	84,739
Other creditors	5,201	2,821
Accruals and deferred income	527,024	420,202
	<u>600,094</u>	<u>516,328</u>

17 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				
	Balance at 1 January 2022 €	Incoming resources €	Resources expended €	Transfers €	Balance at 31 December 2022 €
Uveal Melanoma	8,570	-	(8,570)	-	-
Ovarian appeal	-	26,360	(26,360)	-	-
Pancreatic (T Daly)	24,001	35,830	(33,598)	-	26,233
Tumour Immunology (5FTF)	437,610	195,783	(49,882)	(583,511)	-
Tumour Microbio	27,079	174,754	(126,838)	-	74,995
Brain	-	105,138	(83,280)	-	21,858
Liver / HIP	-	67,000	-	-	67,000
Breast	-	23,573	(23,573)	-	-
	<u>497,260</u>	<u>628,438</u>	<u>(352,101)</u>	<u>(583,511)</u>	<u>190,086</u>

18 Analysis of net assets between funds

	General Funds €	Restricted Funds €	Total €
Fund balances at 31 December 2022 are represented by:			
Tangible assets	28,922	-	28,922
Current assets/(liabilities)	384,206	190,086	574,292
	<u>413,128</u>	<u>190,086</u>	<u>603,214</u>

BREAKTHROUGH CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

19 Events after the reporting date

The trustees are of the view that the fundraising climate for 2023 could remain challenging as a result of the conflict in Ukraine, other external events like the earthquake in Syria / Turkey and the impact of inflation on supporters. This could have some impact on the income of the company for 2023. Nonetheless the trustees are of the view that this will not impact on the ability of the company to operate as a going concern due to the significant levels of reserves the company has at the end of 2022 and the ability of the company to manage its expenditure on research and other activities. A new four year strategy commencing in 2023 is targeting investment to grow the income of the company and enable increasing our research investment.

20 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2022 €	2021 €
Aggregate compensation	84,734	69,021

21 Cash generated from operations

	2022 €	2021 €
(Deficit)/surplus for the year	(151,604)	317,454
Adjustments for:		
Depreciation and impairment of tangible fixed assets	5,521	4,055
Movements in working capital:		
(Increase)/decrease in debtors	(47,503)	453
Increase in creditors	79,961	111,076
Cash (absorbed by)/generated from operations	(113,625)	433,038

22 Analysis of changes in net funds

	1 January 2022 €	Cash flows €	31 December 2022 €
Cash at bank and in hand	1,243,375	(136,997)	1,106,378
Company visa card	-	(3,805)	(3,805)
	1,243,375	(140,802)	1,102,573

23 Approval of financial statements

The board of directors approved the financial statements for issue on the 11/09/2023.